ID
31306
Description
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Any adverse experience is defined as a new or worsening pre-existing medical condition or complication occurring while on study, regardless of its perceived relationship to the drug. Please record all adverse experiences from the time of study entry through the Week 13 visit.
Keywords
Versions (1)
- 8/12/18 8/12/18 -
Copyright Holder
see clinicaltrials.gov
Uploaded on
August 12, 2018
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755
Adverse Experiences
- StudyEvent: ODM
Description
Adverse Experiences
Alias
- UMLS CUI-1
- C0877248
Description
Adverse Event; Number
Data type
integer
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0237753
Description
Adverse Event
Data type
text
Alias
- UMLS CUI [1]
- C0877248
Description
Adverse Event; CTC grade
Data type
text
Alias
- UMLS CUI [1]
- C2985911
Description
Adverse event, serious
Data type
boolean
Alias
- UMLS CUI [1]
- C1519255
Description
Adverse event; start date
Data type
date
Alias
- UMLS CUI [1]
- C2697888
Description
Adverse event; end date
Data type
date
Alias
- UMLS CUI [1]
- C2697886
Description
Adverse event; frequency
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0439603
Description
Adverse event; Therapeutic Measures; Drugs
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C0013227
Description
Adverse event; Therapeutic Measures; Other
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C0205394
Description
Adverse event; Therapeutic Measures; Other; Specification
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C0205394
- UMLS CUI [1,4]
- C2348235
Description
Adverse event; Outcome
Data type
text
Alias
- UMLS CUI [1]
- C1705586
Description
Adverse event; Relationship; Drug
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0439849
- UMLS CUI [1,3]
- C0013227
Description
Adverse event; Relationship; Disease
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0439849
- UMLS CUI [1,3]
- C0012634
Similar models
Adverse Experiences
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C2348235 (UMLS CUI [1,4])
C0439849 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0439849 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
No comments